secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001326732-25-000052
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor Q1 net loss narrows to $48.4M; CDO Valente resigns, Phase 2b UC study on track
--------------------------------------------------------------------------------

- Q1 revenue $32.7M (up from $16.0M YoY); net loss $48.4M (-$0.66 EPS) versus $73.4M (-$1.20 EPS) prior year.
- Cash $693.5M at March 31; expects year-end 2025 cash $535-585M, funding operations into 2028.
- Nancy Valente, EVP & CDO, to resign June 6, 2025, remain as senior advisor; clinical leaders report to CEO.
- XmAb942 interim Phase 1 shows half-life >71 days, supports Q12W maintenance dosing; Phase 2b XENITH-UC starts H2 2025.
- Earned $12.5M milestone from Incyte for tafasitamab sBLA acceptance, $2.0M from Vir for tobevibart Phase 3 start.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000052/0001326732-25-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000052/xncr-20250505.htm
  HTML page:      https://secwatch.observer/filing/0001326732-25-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer